Update with the development of Ebola vaccines and implications to inform policy recommendations

Introduction & questions for SAGE’s consideration

Fred Were, Co-chair, Ebola WG
SAGE meeting, 25–27 April 2017
WG on Ebola vaccines and vaccination

**Terms of Reference**

To facilitate the review, the Working Group will provide technical advice and support to the WHO secretariat by reviewing:

- **the essential evidence** required for making policy recommendations and on strategies for deployment of vaccines.

- **the available epidemiological data** to define the risk of disease and mortality in different population groups in order to allow prioritization of vaccination.

- the evidence, as it becomes available, on **the safety, and efficacy of candidate vaccines**, including the optimal vaccination schedules to be used for each vaccine.
the data on the **projected impact of different vaccination strategies** generated by mathematical models.

- the **projections of vaccine supply** to inform recommendations on the deployment of vaccines.

Prepare the synthesis of the above data for presentation to SAGE and in drafting recommendations for consideration by SAGE.
|   | Introduction                                                                 | F. Were  
|   |                                                                             | Co-Chair of the Ebola WG  
| 2 | Overview of Ebola epidemiology                                             | D. Heymann  
|   |                                                                             | LSHTM, Public Health England and Chattam House  
| 3 | Update on Ebola candidate vaccines R&D plans                                | A.M Henao-Restrepo  
|   |                                                                             | Initiative for Vaccine Research, WHO  
| 4 | Observed and forecasted impact of different candidate Ebola vaccines        | A. Camacho  
|   | immunization strategies and target populations                            | B. LSHTM & Epicentre  
| 5 | Access to Ebola vaccines before licensure and after licensure              | M. Serafini,  
|   |                                                                             | MSF Switzerland  
| 6 | Conclusions and proposed recommendations                                   | H. Rees  
|   |                                                                             | Co- Chair of the Ebola WG  
| 7 | Discussion                                                                  |
WG meeting on 14–15 March 2017
Evidence reviewed

1. EVD epidemiology
2. Characteristics of candidate Ebola vaccines in clinical development
3. Private reports by each vaccine developer (closed session SAGE WG Members only)
4. Modelled impact of different vaccine delivery strategies
5. rVSVΔG-ZEBOV-GP use under Expand Access framework during flare-ups
6. Strategies to ensure Pre-licensure and Post-licensure access
7. WHO Target Product Profiles and current regulatory pathways
8. Current and planned efforts to further support epidemic vaccine R&D
9. Preliminary conclusions and deliberation on proposed questions for SAGE (closed session SAGE WG Members only)
Questions for SAGE

1. Are there remaining challenges that may prevent access to Ebola vaccines in future outbreaks? If yes, can SAGE make recommendations on how these might be addressed?

2. Is the current evidence sufficient for SAGE to make recommendations regarding the use of Ebola vaccines in case of another Ebola outbreak (pre-licensure and/or post licensure)?
   - If yes, which recommendations can be proposed?
   - If not, what key data are missing?
Thank you